Aging
Drug research and approvals for aging: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 17, 2026, 570 studies of aging are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 570
- Trials authorized in Canada: 1
- FDA orphan approvals: 0
- EU medicines: 1
Recruiting Now
Newest start dates first, of 570 recruiting on ClinicalTrials.gov ↗- The Effects of Increased Water Intake on Muscle Function, Physical Performance, and Endocrine Regulation in…NCT07892742 · Not applicable · Polytechnic University of Santarém · starts Jan 1, 2027
- Neuroplasticity Enhancement From Cognitive Training Reinforced by PsilocybinNCT07721467 · Phase 2 · National Institute on Aging (NIA) · starts Nov 19, 2026
- PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)NCT07099053 · Not reported · National Institute on Aging (NIA) · starts Nov 19, 2026
- Taiwan Blue Zone Pilot StudyNCT07937969 · Not applicable · National Health Research Institutes, Taiwan · starts Nov 17, 2026
- Carbon Dioxide Administration and Brain Waste ClearanceNCT07357090 · Not applicable · Andrew Mayer · starts Nov 10, 2026
- Vascular Aging and Microcirculation: Physiological Aspects of Vascular Aging in the Elderly Population (VAMP-Aging)NCT07563725 · Not reported · National Institute of Cardiology, Laranjeiras, Brazil · starts Nov 4, 2026
- Experimental PBT Study in Fall-prone SubjectsNCT07654335 · Not applicable · University Rehabilitation Institute, Republic of Slovenia · starts Nov 2, 2026
- Effect of Collagen and MSM Supplementation on Advanced Glycation End Products in Skin: Part B of the TO-COSKIN4 StudyNCT07925437 · Not applicable · VIST - Faculty of Applied Sciences · starts Nov 1, 2026
- Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral NeuropathyNCT07822932 · Not applicable · University of Miami · starts Nov 1, 2026
- Ultraformer MPT Combined With Fractional CO2 Versus Fractional CO2 Alone for Facial RejuvenationNCT07896512 · Not applicable · Clinique Face MD · starts Oct 30, 2026
Drug Pipeline
5 in phase 3, 17 in phase 2, 22 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Metformin
- Phase 3 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Onabotulinumtoxina
- Phase 3 Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- Testosterone undecanoate
- Phase 3 Androgen Receptor agonist
- Prasterone
- Phase 3 Unknown
- Ivabradine
- Phase 3 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker
- Sirolimus
- Phase 2 FK506-binding protein 1A inhibitor
- Nicotinamide riboside
- Phase 2
- Nitrous acid
- Phase 2
- Dasatinib anhydrous
- Phase 2 Tyrosine-protein kinase ABL inhibitor
- Acarbose
- Phase 2 Pancreatic alpha-amylase inhibitor
- Influenza virus vaccine
- Phase 2 Biological vaccine - induces immune response
- Quercetin
- Phase 2
- Oxytocin
- Phase 2 Oxytocin receptor agonist
- Somatropin
- Phase 2 Growth hormone receptor agonist
- Cholecalciferol
- Phase 2 Vitamin D receptor agonist
- Capromorelin
- Phase 2 Ghrelin receptor agonist
- Calcium carbonate
- Phase 2
- Oxygen
- Phase 2 Essential for cellular homeostasis
- Resveratrol
- Phase 2
- Ghrelin
- Phase 2
- Sulforaphane
- Phase 2
- Mitoquinone cation
- Phase 2
- Testosterone
- Phase 1 Androgen Receptor agonist
- Nicotine
- Phase 1 Neuronal acetylcholine receptor; alpha4/beta2 agonist
- Diclofenac
- Phase 1 Cyclooxygenase inhibitor
- Everolimus
- Phase 1 FK506-binding protein 1A inhibitor
- Losartan
- Phase 1 Type-1 angiotensin II receptor antagonist
- Nitroprusside
- Phase 1 Soluble guanylate cyclase activator
- Anastrozole
- Phase 1 Cytochrome P450 19A1 inhibitor
- Mecamylamine
- Phase 1 Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator
Showing the 30 furthest along of 44 in trials.
Trials Authorized in Canada
Newest first; search them all in Canada trials| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Aug 29, 2013 | "a single blind, split-face, randomized, pilot study to compare the effects of intradermal & intramuscular treatments with two commercially available botulinum…Botox cosmetic (onabotulinumtoxin a) | Institute Of Cosmetic & Laser Surgery | Pending |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Sep 27, 2019 | NuceivaBotulinum toxin type a | Evolus Pharma B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA